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Adult atopic dermatitis (AD) is associated with over-
weight, obesity and cardiovascular diseases (CVD) in 
Americans, similarly to psoriasis, but no increased risk 
of CVD has been shown in European patients with AD. 
This study investigated the prevalence and risk of gall-
stones in adults with AD and in those with psoriasis as 
a proxy for obesity using nationwide data for all Da-
nish citizens ≥ 30 years of age. Outcome was a diagno-
sis of gallstones. Odds ratios (ORs) were calculated by 
logistic regression (cross-sectional study) and hazard 
ratios (HRs) were estimated by Cox regression (cohort 
study). The study comprised 6,742 patients with AD, 
53,810 patients with psoriasis, and 3,534,164 gene-
ral population subjects. The prevalence of gallstones 
was 3.8%, 3.5% and 5.0% in the general population, 
AD and psoriasis patients, respectively. Adjusted ORs 
were 0.81 (0.71–0.92) for AD and 1.18 (1.14–1.23) for 
psoriasis. During follow-up, adjusted HRs were 0.72 
(0.56–0.90) for AD and 1.10 (1.02–1.18) for psoriasis. 
The findings highlight important differences in obesity 
and lifestyle factors among patients with AD and those 
with psoriasis.
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Atopic dermatitis (AD) is a chronic relapsing inflam-matory skin disease that affects many adults, a lar-
ge number of whom will have lived with their condition 
since childhood (1). Well-established co-morbidities 
include not only food allergies, asthma and rhinitis, 
but also psychiatric conditions, including anxiety, 
depression and attention deficit hyperactivity disorder 
(ADHD) (2–4). However, there is growing interest in 
possible cardiovascular co-morbidities, since chronic 
low-grade inflammation could potentially increase the 
risk of such conditions. For example, US cohorts of 
adult patients with AD and eczema have found increased 
risks of hypertension, angina, heart attack, and stroke, 
as well as pre-diabetes (5, 6). Similarly, a study from 
Taiwan showed a dose-dependent increased risk of 
stroke in patients with AD (7). However, we have not 
been able to replicate the increased risk of cardiovascu-
lar disease (CVD) in adult Danish patients with AD (8). 
We have speculated that the explanation could be a dif-
ference in risk factors between the populations. Indeed, 
a meta-analysis showed that obesity and overweight 
were significantly associated with AD in American and 
Asian populations, but not in Europeans (9). This is in 
line with our clinical impression that Danish patients 
with AD are rarely overweight or obese. Conversely, 
Danish patients with psoriasis have a higher prevalence 
of overweight and obesity (10). In fact, obesity is signi-
ficantly and independently associated with the presence 
and severity of psoriasis (11), probably resulting from 
obesity-induced systemic low-grade inflammation (12, 
13). While obese patients show decreased response to 
anti-psoriatic therapy (14), weight loss has been sug-
gested as a potential therapeutic option for patients with 
psoriasis (15, 16). Hypertension, dyslipidaemia, and 
diabetes also frequently occur in patients with psoriasis, 
and there is a high prevalence of smoking and alcohol 
consumption among these patients (17, 18).
Gallstones (cholelithiasis) is one of the most common 
medical problems leading to surgical intervention in 
Western countries, resulting in approximately 500,000 
cholecystectomies in the US each year (19). Gallstones 
affect approximately 10% of the adult population in the 
USA, whereas in Europe, prevalence rates from 6% in 
Italy to 22% in Norway have been found (20, 21). While 
certain subtypes exist (cholesterol, brown pigment, and 
black pigment gallstones, respectively), in general the 
risk factors predisposing to gallstone formation include 
obesity, diabetes, dyslipidaemia, oestrogen and pregnan-
cy, haemolytic diseases, and cirrhosis (19, 22). Moreover, 
while gallstones may cause subsequent inflammation 
of the gallbladder, inflammation itself does not appear 
to be a significant contributor to the development of 
gallstones (19). 
A fundamental limitation of many large-scale regist-
ries is the lack of data on body mass index (BMI). Since 
gallstones are significantly associated with overweight 
and obesity, these may serve as a useful proxy to examine 
potential differences in obesity between study groups. We 
therefore examined the prevalence and risk of gallstones 
in patients with adult AD and psoriasis, compared with 
the general Danish population, using cross-sectional and 
cohort study designs. 
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MATERIALS AND METHODS
Data sources and study population
Study approval was obtained from the Danish Data Protection 
Agency (ref. 2007-58-0015, int. ref. GEH-2014-018, I-Suite 
02736). Approval from an ethics committee is not required for re-
gistry studies in Denmark. The study was conducted in accordance 
with the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) recommendations (23). 
Denmark has high-quality nationwide administrative registries, 
in which all Danish residents can be linked at the individual level 
(24). The Danish National Patient Register (DNPR) (25) was 
established in 1978, and information on inpatient and outpatient 
(ambulatory) hospital consultations according to the International 
Classification of Diseases, 8th (ICD-8) and 10th revision (ICD-10). 
The validity of data from this register has been described elsewhere 
(26). The 9th revision was never used in Denmark. The Danish 
Registry of Medicinal Products Statistics (27), established in 1994, 
records information on all pharmacy-dispensed medications in 
Denmark, according to the international Anatomical Therapeutic 
Chemical (ATC) classification. Medication dispensed during hos-
pitalization, or given directly from ambulatory clinics, is recorded 
in the DNPR. Information on tax-reported household income is 
recorded by Statistics Denmark (28).
The present study comprised all Danish adults ≥30 years and 
resident in Denmark on 1 January 2008 (i.e. the date of study start 
for all individuals in the cohort study). Subjects were followed 
from study start until 31 December 2012, death, migration, or the 
occurrence of an endpoint, whichever came first. Patients were 
classified as having adult AD if on or after their 18th birthday, but 
prior to the study start, they had received a diagnosis (inpatient 
or ambulatory) of AD by a dermatologist (ICD-8 691 and ICD-10 
L20) recorded in the DNPR. Patients with psoriasis were identi-
fied by either a diagnosis of psoriasis (ICD-8 696.1 and ICD-10 
L40) recorded in the DNPR, or if they had been given at least 2 
prescriptions of topical vitamin D derivatives (ATC code D05AX), 
which is the preferred first-line treatment and used exclusively for 
psoriasis in Denmark. The accuracy of this method has been descri-
bed elsewhere (29). At least 2 prescriptions were required to ensure 
persistent medical therapy. Patients were classified with severe 
disease if they received systemic therapy for AD (methotrexate, 
azathioprine, mycophenolate mofetil, systemic corticosteroids, 
psoralen plus ultraviolet A (PUVA), or cyclosporine) or psoriasis 
(methotrexate, PUVA, retinoids, cyclosporine, adalimumab, efa-
lizumab, etanercept, infliximab, or ustekinumab) consistent with 
severe disease. Patients who did not receive such therapy were 
classified as mild. Collection of data on diabetes, hypertension, 
smoking history, and alcohol abuse has been described in detail 
elsewhere (30–32). From Statistics Denmark we used information 
on tax-reported household income to calculate an age-standardized 
index of socioeconomic status based on the mean gross annual 
income during a 5-year period before study start. Patients with 
gallstones were identified by ICD-8 574 and ICD-10 K80. 
Statistical analysis
This study described baseline characteristics with means and stan-
dard deviations (SDs) for continuous variables and frequencies and 
percentages for categorical variables. The baseline prevalence of 
gallstones was determined as the percentage of individuals who had 
received a diagnosis of gallstones between 1 January 1978 (when 
the DNPR was established) and 1 January 2008. A cross-sectional 
Table I. Baseline characteristics of the study population
 
General population
(n = 3,534,164)
Any AD
(n = 6,742)
Mild AD
(n = 3,394)
Severe AD
(n = 3,348)
Any psoriasis
(n = 53,810)
Mild psoriasis
(n=44,052)
Severe psoriasis
(n=9758)
Age, years, mean (SD) 53.9 (15.3) 45.3 (12.0) 43.5 (10.9) 47.1 (12.8) 57.1 (14.4) 57.0 (14.5) 57.5 (13.7)
Sex, n (%)
  Women 1,806,394 (51.1) 4,369 (64.8) 2,322 (68.4) 2,047 (61.1) 27,274 (50.7) 22,277 (50.6) 4,997 (51.2)
  Men 1,727,770 (48.9) 2,373 (35.2) 1,072 (31.6) 1,301 (38.9) 26,536 (49.3) 21,775 (49.4) 4,761 (48.8)
Socioeconomic status, n (%)
  Lowest 707,377 (20.0) 757 (11.2) 370 (10.9) 387 (11.6) 10,957 (20.4) 8,887 (20.2) 2,070 (21.2)
  Below average 705,814 (20.0) 1,197 (17.8) 542 (16.0) 655 (19.6) 11,897 (22.1) 9,393 (21.3) 2,504 (25.7)
  Average 706,801 (20.0) 1,551 (23.0) 757 (22.3) 794 (23.7) 10,556 (19.6) 8,567 (19.5) 1,989 (20.4)
  Above average 707,822 (20.0) 1,537 (22.8) 777 (22.9) 760 (22.7) 9,554 (17.8) 7,917 (18.0) 1,637 (16.8)
  Highest 706,350 (20.0) 1,700 (25.2) 948 (27.9) 752 (22.5) 10,846 (20.2) 9,288 (21.1) 1,558 (16.0)
Smoking, n (%) 322,343 (9.1) 717 (10.6) 280 (8.3) 437 (13.1) 7,001 (13.0) 5,518 (12.5) 1,483 (15.2)
Alcohol abuse, n (%) 46,010 (1.3) 98 (1.5) 44 (1.3) 54 (1.6) 1,084 (2.0) 872 (2.0) 212 (2.2)
Diabetes, n (%) 149,307 (4.2) 126 (1.9) 47 (1.4) 79 (2.4) 3,971 (7.4) 3,139 (7.1) 832 (8.5)
Hypertension, n (%) 515,365 (14.6) 481 (7.1) 171 (5.0) 310 (9.3) 11,414 (21.2) 9,250 (21.0) 2,164 (22.2)
Cholesterol-lowering drugsa, n (%) 391,469 (11.1) 379 (5.6) 130 (3.8) 249 (7.4) 8,886 (16.5) 7,243 (16.4) 1,643 (16.8)
Prevalent gallstones at baseline, n (%) 134,374 (3.8) 237 (3.5) 112 (3.3) 125 (3.7) 2,709 (5.0) 2,111 (4.8) 598 (6.1)
aClaimed prescription within last 6 months.
AD: atopic dermatitis; SD: standard deviation.
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Fig. 1. Baseline prevalence of gallstones among the 
general population, patients with adult atopic dermatitis 
(AD), and patients with psoriasis, respectively. The 
baseline prevalence of gallstones was not significantly different 
(p = 0.218) between patients with adult AD and the general 
population, but significantly higher (p < 0.001) among patients 
with psoriasis (including mild and severe psoriasis) compared 
with the general population.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
629Atopic dermatitis, psoriasis and gallstones
Acta Derm Venereol 2017
design was applied using logistic regression models to assess the 
odds ratios (ORs) of gallstones on 1 January 2008. In a cohort 
study design patients were followed from 1 January 2008 and until 
death, migration, 31 December 2012, or a diagnosis of gallstones, 
whichever came first. Incidence rates per 1,000 person-years were 
estimated, and Cox regression models were used to obtain hazard 
ratios (HRs) for the risk of incident gallstones. Incidence of gall-
stones during follow-up was calculated for all individuals without a 
history of gallstones prior to study start. ORs and HRs for gallstones 
were calculated as age- and sex-adjusted, and fully adjusted (in 
which age, sex, socioeconomic status, and healthcare consumption 
(number of clinic visits) were considered). Sensitivity analyses were 
performed with additional adjustments for diabetes, alcohol abuse, 
and cholesterol-lowering drug use, as well as additional adjustment 
for inflammatory bowel disease (IBD). Two-tailed p-values < 0.05 
were considered statistically significant and results were reported 
with 95% confidence intervals (95% CIs), where applicable. All 
analyses were performed with SAS statistical software version 9.4 
(SAS Institute Inc. Cary, NC, USA) and STATA software version 
13.0 (StataCorp, College Station, TX, USA)
RESULTS
The study cohort comprised 3,534,164 subjects from the 
general population, 6,742 patients with adult AD, and 
53,810 patients with psoriasis. A total of 3,394 patients 
had mild AD, and 3,348 had severe AD. Among patients 
with psoriasis, 44,052 had mild, and 9,758 had severe 
psoriasis, respectively. The mean ages at baseline ranged 
from 43.5 to 57.5 years across the groups, and there 
was an equal sex distribution, except among patients 
with adult AD, who were predominantly female (Table 
I). The prevalence of smoking and alcohol abuse was 
comparable between adult AD patients and the general 
population, but higher among patients with psoriasis. 
Notably, compared with the general population, diabetes, 
hypertension, and cholesterol-lowering drug use was 
significantly less frequent among adult AD patients, but 
occurred more often among patients with psoriasis.
At baseline, the period prevalence (from 1978 until 
2008) of gallstones was 3.8%, 3.5% and 5.0% for the 
general population, patients with AD, and patients with 
psoriasis, respectively. Stratified by disease severity, the 
prevalence was 3.3% and 3.7% in mild and severe AD, 
and 4.8% and 6.1% in mild and severe psoriasis (Fig. 
1). Using a cross-sectional design, the OR of gallstones 
was significantly decreased among adult AD patients 
(adjusted OR 0.81; 0.71–0.92), but increased among pso-
riasis patients (adjusted OR 1.18; 1.14–1.23). Adjusted 
ORs for mild and severe AD were 0.78 (0.65–0.94) and 
0.84 (0.70–1.01), respectively, and for psoriasis 1.15 
(1.10–1.20) and 1.31 (1.20–1.42), respectively (Table 
II).
During follow-up in the cohort study, there were 
44,353, 76 and 795 cases of incident (new-onset) gall-
stones among the general population, patients with AD, 
and patients with psoriasis, respectively, as shown in 
Table III. The adjusted HR of incident gallstones was 
0.72 (0.56–0.90) for adult AD, and 1.10 (1.02–1.18) for 
psoriasis. Stratified by disease severity, the 5-year risk 
of incident gallstones was significantly decreased among 
patients with mild AD (adjusted HR 0.57; 0.40–0.81) 
and also showed a decreased risk, albeit not statistically 
significant, among patients with severe AD (adjusted HR 
0.86; 0.64–1.16). For patients with mild psoriasis the 
risk of gallstones was not increased (adjusted HR 1.07; 
0.98–1.16; p = 0.1145), but the risk was significantly 
increased among patients with severe psoriasis (adjusted 
HR 1.24; 1.07–1.44) (Table IV). In sensitivity analyses 
with additional adjustment for diabetes, alcohol abuse, 
and cholesterol-lowering drug use, as well as in analy-
ses further adjusted for IBD, there were no significant 
changes in any of the reported ORs or HRs, compared 
with the primary analyses (data not shown).
DISCUSSION
This nationwide study of the adult Danish population 
found an increased prevalence and risk of gallstones in 
patients with psoriasis. However, the prevalence and 
risk were significantly lower among patients with AD 
compared with the general population. These findings 
support the notion that patients with psoriasis tend to be 
obese and overweight, while the same does not hold true 
for Danish adults with AD.
While 2 of 3 studies from the US have supported an 
association of AD with CVD (5, 6, 33), one Danish study 
Table II. Odds ratios for association between adult atopic dermatitis 
and psoriasis, and gallstones at baseline (cross-sectional study design)
Gallstones
Age- and sex-adjusted Fully adjusteda
OR 95% CI p-value OR 95% CI p-value
Any AD 1.04 0.91–1.18 0.5982 0.81 0.71–0.92 0.0016
Mild AD 0.99 0.82–1.19 0.8857 0.78 0.65–0.94 0.0109
Severe AD 1.08 0.91–1.30 0.3766 0.84 0.70–1.01 0.0611
Any psoriasis 1.27 1.22–1.32 < 0.0001 1.18 1.14–1.23 < 0.0001
Mild psoriasis 1.21 1.16–1.26 < 0.0001 1.15 1.10–1.20 < 0.0001
Severe psoriasis 1.54 1.42–1.67 < 0.0001 1.31 1.20–1.42 < 0.0001
aAge, sex, socioeconomic status, and healthcare consumption.
OR: odds ratio; CI: confidence interval; AD: atopic dermatitis.
Table III. Summary of number of new events, follow-up time, and incidence rates of incident gallstones/1000 person-years (PY)
 General population Any AD Mild AD Severe AD Any psoriasis Mild psoriasis Severe psoriasis
Gallstones
  Follow-up time, years 16,198,924 31,692 16,121 15,571 239,697 196,988 42,709
  Number of events 44,353 76 30 46 795 617 178
  Incidence rate/1,000 PY 2.74 2.40 1.86 2.95 3.32 3.13 4.17
  95% CI 2.71–2.76 1.92–3.00 1.30–2.66 2.21–3.94 3.09–3.56 2.89–3.39 3.60–4.83
CI: confidence interval; AD: atopic dermatitis; PY: person years.
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could not confirm an association following adjustment for 
risk factors including tobacco smoking (8). One explana-
tion could be that adult patients with AD in Denmark and 
the US have different risk profiles including overweight 
and obesity (9). Studies have shown that US paediatric 
and adult patients with AD have less physical activity 
than controls, whereas a study from Sweden showed no 
difference in 20–34-year-olds (34–36). While, to our 
knowledge, there are no published data on BMI in Danish 
adults with AD, we have previously performed a cohort 
study including 344 adults with AD and 2,999 general 
population controls in Denmark (37). In that cohort, the 
mean ± SD BMI was 25.9 ± 5.2 and 25.9 ± 4.6) kg/m2 in 
adults with AD and the general population, respectively 
(unpublished data). 
Conversely, the link between psoriasis and obesity is 
well-established (11, 38) and obese patients with pso-
riasis are less likely to achieve a satisfactory treatment 
response compared with lean individuals (15). 
While a disease-severity-dependent risk of co-morbidi-
ties in patients with psoriasis is often attributed to syste-
mic low-grade inflammation (39), formation of gallstones 
is generally considered to be non-inflammatory in nature 
(19). Thus, it is likely that the observed discrepancy in 
risk of gallstones between AD and psoriasis is due to 
body weight rather than to differences in their inflam-
matory pathways. In further support of such a hypothesis, 
it is interesting to note the markedly higher prevalence of 
diabetes and cholesterol-lowering drug use (suggestive 
of hyperlipidaemia) among patients with psoriasis in 
our study, as opposed to the very modest prevalence in 
patients with AD compared with the general population.
Certain limitations apply to the interpretation of the 
present results. Due to the observational nature of our 
study, we cannot claim a causal link. While differences 
in BMI would be a logical explanation, we cannot re-
fute that other factors may also have played a role. It 
is well-recognized that gallstones are more common 
among women and that the risk increases with age (19). 
Thus, although we adjusted for such differences in our 
model, residual confounding from other risk factors 
could have affected our results. Also, while we sampled 
patients with psoriasis from the general population and 
hospital settings, data on adult AD were available only 
from patients seen in hospital (including ambulatory) 
clinics. Indeed, it is plausible that such patients may 
comprise the more severe cases of AD. However, this 
would arguably have biased the results towards the null, 
i.e. no difference, suggesting that the true difference may 
be even higher. Lastly, the Danish population is predo-
minantly of Caucasian decent and the results should be 
interpreted accordingly. 
In conclusion, this study found a significantly de-
creased risk of gallstones in patients with adult AD, but 
the risk was increased in patients with psoriasis. The 
findings may suggest important differences in obesity 
and modifiable lifestyle factors among patients with AD 
and those with psoriasis.
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